1
|
Arnold SM, Graham WW, Valentino J, Brill Y, Regine W, Spring P, Given C, Mohiuddin M, St Claire W, Kudrimoti M. Results of intraarterial cisplatin and hyperfractionated radiotherapy in locally advanced cancer of the oropharynx and oral cavity. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5563] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5563 Background: Intraarterial cisplatin and hyperfractionated radiation (HYPERADPLAT) is an accepted therapy for Stage III and IV head and neck cancer. We present long-term follow-up of patients with OP and OC cancer treated with HYPERADPLAT at a single institution. Methods: 44 patients with Stage III-IV squamous cell carcinomas of the OP or OC were treated with the HYPERRADPLAT regimen consisting of external beam radiotherapy (76.8–81.6 Gy) delivered in 1.2 Gy BID fractions with intraarterial cisplatin (150 mg/m2) administered when patients had reached 60 Gy. Tumor response, disease free survival (DFS), overall survival (OS), and toxicity were assessed for all patients according to NCI CCT criteria. Results: Of 44 patients, 21 had tumors of the base of tongue, 14-tonsil, 4-floor of mouth, and 5-other. Eighty eight percent of patients had T4 tumors and 7% had T3 tumors. Complete tumor response was observed in 86% of patients and 14% had a partial response. Lymph node metastases were present in 84% of patients with 78% of node positive patients having a complete nodal response and 19% with a partial response to treatment. Three-year DFS was 55% and OS was 45%. Locoregional recurrence was noted in 30% of patients and 16% had distant failure. Overall recurrence was noted in 47% of patients with a median time to recurrence of 8 months (range 4–55 months). Median weight loss during treatment was 9% of initial body weight and 28 patients required a feeding tube within 6 months of starting treatment. Grade 3 mucositis was noted in 68% of patients and 3 patients developed Grade 4 toxicity (2 mucosal, 1 hematologic). Conclusions: HYPERRADPLAT results in excellent tumor control that is well tolerated with minimal Grade 4 toxicity in patients with advanced poor prognosis cancers of the OP and OC. These results compare favorably with historically reported control rates and response for patients with a significantly high percentage of T4 tumors of the oropharynx and oral cavity. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. M. Arnold
- University of Kentucky, Lexington, KY; University of Maryland, Baltimore, MD; University of Arkansas, Little Rock, AR; Geisinger Medical System, Wilkes Barre, PA
| | - W. W. Graham
- University of Kentucky, Lexington, KY; University of Maryland, Baltimore, MD; University of Arkansas, Little Rock, AR; Geisinger Medical System, Wilkes Barre, PA
| | - J. Valentino
- University of Kentucky, Lexington, KY; University of Maryland, Baltimore, MD; University of Arkansas, Little Rock, AR; Geisinger Medical System, Wilkes Barre, PA
| | - Y. Brill
- University of Kentucky, Lexington, KY; University of Maryland, Baltimore, MD; University of Arkansas, Little Rock, AR; Geisinger Medical System, Wilkes Barre, PA
| | - W. Regine
- University of Kentucky, Lexington, KY; University of Maryland, Baltimore, MD; University of Arkansas, Little Rock, AR; Geisinger Medical System, Wilkes Barre, PA
| | - P. Spring
- University of Kentucky, Lexington, KY; University of Maryland, Baltimore, MD; University of Arkansas, Little Rock, AR; Geisinger Medical System, Wilkes Barre, PA
| | - C. Given
- University of Kentucky, Lexington, KY; University of Maryland, Baltimore, MD; University of Arkansas, Little Rock, AR; Geisinger Medical System, Wilkes Barre, PA
| | - M. Mohiuddin
- University of Kentucky, Lexington, KY; University of Maryland, Baltimore, MD; University of Arkansas, Little Rock, AR; Geisinger Medical System, Wilkes Barre, PA
| | - W. St Claire
- University of Kentucky, Lexington, KY; University of Maryland, Baltimore, MD; University of Arkansas, Little Rock, AR; Geisinger Medical System, Wilkes Barre, PA
| | - M. Kudrimoti
- University of Kentucky, Lexington, KY; University of Maryland, Baltimore, MD; University of Arkansas, Little Rock, AR; Geisinger Medical System, Wilkes Barre, PA
| |
Collapse
|